25 XP   0   0   10

Alx Oncology Holdings 
Buy, Hold or Sell?

Let's analyse Alx Oncology Holdings  together

PenkeI guess you are interested in Alx Oncology Holdings . Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Alx Oncology Holdings . At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Alx Oncology Holdings 

I send you an email if I find something interesting about Alx Oncology Holdings .

Quick analysis of Alx Oncology Holdings  (30 sec.)










What can you expect buying and holding a share of Alx Oncology Holdings ? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
10.5%

What is your share worth?

Current worth
$3.39
Expected worth in 1 year
$1.01
How sure are you?
15.8%

+ What do you gain per year?

Total Gains per Share
$-2.37
Return On Investment
-21.7%

For what price can you sell your share?

Current Price per Share
$10.95
Expected price per share
$10.16 - $13.36
How sure are you?
50%

1. Valuation of Alx Oncology Holdings  (5 min.)




Live pricePrice per Share (EOD)

$10.95

Intrinsic Value Per Share

$-32.52 - $-38.39

Total Value Per Share

$-29.13 - $-35.01

2. Growth of Alx Oncology Holdings  (5 min.)




Is Alx Oncology Holdings  growing?

Current yearPrevious yearGrowGrow %
How rich?$168.7m$327.4m-$106.1m-48.0%

How much money is Alx Oncology Holdings  making?

Current yearPrevious yearGrowGrow %
Making money-$36.1m-$29.6m-$6.4m-17.8%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Alx Oncology Holdings  (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#293 / 1037

Most Revenue
#934 / 1037

Most Profit
#874 / 1037

Most Efficient
#378 / 1037

What can you expect buying and holding a share of Alx Oncology Holdings ? (5 min.)

Welcome investor! Alx Oncology Holdings 's management wants to use your money to grow the business. In return you get a share of Alx Oncology Holdings .

What can you expect buying and holding a share of Alx Oncology Holdings ?

First you should know what it really means to hold a share of Alx Oncology Holdings . And how you can make/lose money.

Speculation

The Price per Share of Alx Oncology Holdings  is $10.95. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Alx Oncology Holdings .
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Alx Oncology Holdings , you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.39. Based on the TTM, the Book Value Change Per Share is $-0.59 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.49 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Alx Oncology Holdings .

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.02-9.3%-0.73-6.7%-0.61-5.6%-0.42-3.8%-0.42-3.8%
Usd Book Value Change Per Share-0.88-8.1%-0.59-5.4%-0.49-4.5%0.181.6%0.181.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.88-8.1%-0.59-5.4%-0.49-4.5%0.181.6%0.181.6%
Usd Price Per Share4.80-7.03-14.01-21.60-21.60-
Price to Earnings Ratio-1.17--2.59--6.11--14.72--14.72-
Price-to-Total Gains Ratio-5.44--13.15--30.69--43.05--43.05-
Price to Book Ratio1.42-1.56-2.08-2.48-2.48-
Price-to-Total Gains Ratio-5.44--13.15--30.69--43.05--43.05-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share10.95
Number of shares91
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.590.18
Usd Total Gains Per Share-0.590.18
Gains per Quarter (91 shares)-53.9816.23
Gains per Year (91 shares)-215.9364.91
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-216-22606555
20-432-4420130120
30-648-6580195185
40-864-8740260250
50-1080-10900324315
60-1296-13060389380
70-1511-15220454445
80-1727-17380519510
90-1943-19540584575
100-2159-21700649640

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.019.00.00.0%0.019.00.00.0%0.019.00.00.0%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%3.013.03.015.8%3.013.03.015.8%3.013.03.015.8%
Dividend per Share0.00.04.00.0%2.00.010.016.7%2.00.017.010.5%2.00.017.010.5%2.00.017.010.5%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%3.013.03.015.8%3.013.03.015.8%3.013.03.015.8%

Fundamentals of Alx Oncology Holdings 

About Alx Oncology Holdings 

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer. The company's pre-clinical program focuses on the development of ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has collaboration agreements with Merck for a Phase 2 trial evaluating evorpacept in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial for the treatment of HER2-expressing breast cancer and other solid tumors; Tallac Therapeutics, Inc. for the development of a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses; and the Quantum Leap Healthcare Collaborative to sponsor and manage a Phase 1 trial to evaluate evorpacept in combination with fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2024-02-27 16:49:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Alx Oncology Holdings .

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Alx Oncology Holdings  earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Alx Oncology Holdings  to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Alx Oncology Holdings :

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-83,737,976.3%+83,737,976.3%
5Y-83,737,976.3%10Y-83,737,976.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--172.8%+172.8%
TTM--206.5%+206.5%
YOY--251.7%+251.7%
5Y-83,737,976.3%-465.8%-83,737,510.5%
10Y-83,737,976.3%-595.4%-83,737,380.9%
1.1.2. Return on Assets

Shows how efficient Alx Oncology Holdings  is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Alx Oncology Holdings  to the Biotechnology industry mean.
  • -23.2% Return on Assets means that Alx Oncology Holdings  generated $-0.23 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Alx Oncology Holdings :

  • The MRQ is -23.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -14.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-23.2%TTM-14.3%-8.8%
TTM-14.3%YOY-8.5%-5.8%
TTM-14.3%5Y-10.6%-3.7%
5Y-10.6%10Y-10.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-23.2%-12.4%-10.8%
TTM-14.3%-12.2%-2.1%
YOY-8.5%-11.1%+2.6%
5Y-10.6%-13.6%+3.0%
10Y-10.6%-15.1%+4.5%
1.1.3. Return on Equity

Shows how efficient Alx Oncology Holdings  is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Alx Oncology Holdings  to the Biotechnology industry mean.
  • 0.0% Return on Equity means Alx Oncology Holdings  generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Alx Oncology Holdings :

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-7.0%+7.0%
TTM-7.0%YOY-7.3%+0.3%
TTM-7.0%5Y-5.1%-1.9%
5Y-5.1%10Y-5.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--15.8%+15.8%
TTM-7.0%-15.8%+8.8%
YOY-7.3%-14.1%+6.8%
5Y-5.1%-18.3%+13.2%
10Y-5.1%-19.4%+14.3%

1.2. Operating Efficiency of Alx Oncology Holdings .

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Alx Oncology Holdings  is operating .

  • Measures how much profit Alx Oncology Holdings  makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Alx Oncology Holdings  to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Alx Oncology Holdings :

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-79,505,144.0%+79,505,144.0%
5Y-79,505,144.0%10Y-79,505,144.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--314.9%+314.9%
TTM--211.1%+211.1%
YOY--276.2%+276.2%
5Y-79,505,144.0%-459.9%-79,504,684.1%
10Y-79,505,144.0%-596.5%-79,504,547.5%
1.2.2. Operating Ratio

Measures how efficient Alx Oncology Holdings  is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Alx Oncology Holdings :

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y795,051.774-795,051.774
5Y795,051.77410Y795,051.7740.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.876-2.876
TTM-3.223-3.223
YOY-3.547-3.547
5Y795,051.7745.795+795,045.979
10Y795,051.7747.396+795,044.378

1.3. Liquidity of Alx Oncology Holdings .

1.3. Liquidity
1.3.1. Current Ratio

Measures if Alx Oncology Holdings  is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.66 means the company has $5.66 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Alx Oncology Holdings :

  • The MRQ is 5.665. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.587. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.665TTM9.587-3.922
TTM9.587YOY17.437-7.850
TTM9.5875Y18.301-8.714
5Y18.30110Y18.3010.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.6653.992+1.673
TTM9.5874.478+5.109
YOY17.4375.562+11.875
5Y18.3016.255+12.046
10Y18.3016.509+11.792
1.3.2. Quick Ratio

Measures if Alx Oncology Holdings  is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Alx Oncology Holdings  to the Biotechnology industry mean.
  • A Quick Ratio of 10.46 means the company can pay off $10.46 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Alx Oncology Holdings :

  • The MRQ is 10.457. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 17.054. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ10.457TTM17.054-6.598
TTM17.054YOY24.718-7.664
TTM17.0545Y21.322-4.268
5Y21.32210Y21.3220.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.4573.662+6.795
TTM17.0544.184+12.870
YOY24.7185.484+19.234
5Y21.3226.041+15.281
10Y21.3226.333+14.989

1.4. Solvency of Alx Oncology Holdings .

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Alx Oncology Holdings  assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Alx Oncology Holdings  to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.23 means that Alx Oncology Holdings  assets are financed with 23.3% credit (debt) and the remaining percentage (100% - 23.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Alx Oncology Holdings :

  • The MRQ is 0.233. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.161. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.233TTM0.161+0.072
TTM0.161YOY0.071+0.090
TTM0.1615Y0.174-0.013
5Y0.17410Y0.1740.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2330.331-0.098
TTM0.1610.325-0.164
YOY0.0710.264-0.193
5Y0.1740.371-0.197
10Y0.1740.380-0.206
1.4.2. Debt to Equity Ratio

Measures if Alx Oncology Holdings  is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Alx Oncology Holdings  to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Alx Oncology Holdings :

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.078-0.078
TTM0.078YOY0.065+0.013
TTM0.0785Y0.104-0.025
5Y0.10410Y0.1040.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.371-0.371
TTM0.0780.396-0.318
YOY0.0650.332-0.267
5Y0.1040.428-0.324
10Y0.1040.479-0.375

2. Market Valuation of Alx Oncology Holdings 

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Alx Oncology Holdings  generates.

  • Above 15 is considered overpriced but always compare Alx Oncology Holdings  to the Biotechnology industry mean.
  • A PE ratio of -1.17 means the investor is paying $-1.17 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Alx Oncology Holdings :

  • The EOD is -2.675. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.172. Based on the earnings, the company is expensive. -2
  • The TTM is -2.587. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.675MRQ-1.172-1.502
MRQ-1.172TTM-2.587+1.414
TTM-2.587YOY-6.107+3.520
TTM-2.5875Y-14.720+12.134
5Y-14.72010Y-14.7200.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.675-2.699+0.024
MRQ-1.172-2.251+1.079
TTM-2.587-2.823+0.236
YOY-6.107-4.293-1.814
5Y-14.720-6.216-8.504
10Y-14.720-6.249-8.471
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Alx Oncology Holdings :

  • The EOD is -4.568. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.002. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.360. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.568MRQ-2.002-2.566
MRQ-2.002TTM-3.360+1.357
TTM-3.360YOY-7.934+4.574
TTM-3.3605Y-22.169+18.809
5Y-22.16910Y-22.1690.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.568-3.506-1.062
MRQ-2.002-2.833+0.831
TTM-3.360-3.461+0.101
YOY-7.934-5.896-2.038
5Y-22.169-8.460-13.709
10Y-22.169-8.868-13.301
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Alx Oncology Holdings  is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.42 means the investor is paying $1.42 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Alx Oncology Holdings :

  • The EOD is 3.233. Based on the equity, the company is fair priced.
  • The MRQ is 1.417. Based on the equity, the company is underpriced. +1
  • The TTM is 1.561. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.233MRQ1.417+1.816
MRQ1.417TTM1.561-0.144
TTM1.561YOY2.084-0.523
TTM1.5615Y2.479-0.918
5Y2.47910Y2.4790.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.2332.111+1.122
MRQ1.4171.879-0.462
TTM1.5612.119-0.558
YOY2.0842.970-0.886
5Y2.4793.686-1.207
10Y2.4794.058-1.579
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Alx Oncology Holdings .

3.1. Institutions holding Alx Oncology Holdings 

Institutions are holding 98.319% of the shares of Alx Oncology Holdings .

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30venBio Partners LLC19.470413.2026969992500
2023-09-30FMR Inc11.22460.00235591947-538592-8.7854
2023-09-30Vivo Capital, LLC8.47082.2192422004800
2023-09-30Orbimed Advisors, LLC5.76290.2927287100000
2023-09-30BlackRock Inc3.69940.00031843019542593.0333
2023-09-30Redmile Group, LLC2.57590.2931128328900
2023-09-30BRAIDWELL LP2.50890.1896124990000
2023-09-30Vanguard Group Inc2.02380.0001100823616480.1637
2023-09-30Logos Global Management LP2.00730.6404100000000
2023-09-30Cormorant Asset Management, LLC1.22860.171461207900
2023-09-30Geode Capital Management, LLC0.88940.0003443067-1231-0.2771
2023-09-30Citadel Advisors Llc0.85350.0004425217222934110.209
2023-09-30State Street Corporation0.78160.000138935979402.0817
2023-09-30Morgan Stanley - Brokerage Accounts0.66940.00023334839063737.3228
2023-09-30Renaissance Technologies Corp0.42650.00172125002970016.2473
2023-12-31Federated Hermes Inc0.39450.0073196536-54824-21.8109
2023-09-30Northern Trust Corp0.38440.0002191524-1178-0.6113
2023-09-30Charles Schwab Investment Management Inc0.28250.0002140734-24817-14.9905
2023-12-31Dimensional Fund Advisors, Inc.0.26940.0006134222-517-0.3837
2023-09-30Goldman Sachs Group Inc0.26320.0001131127-48640-27.0572
Total 64.18717.022831977212-262681-0.8%

3.2. Funds holding Alx Oncology Holdings 

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31HBM Healthcare Investments AG Ord3.01111.1187150000064596275.6362
2023-11-30Fidelity Small Cap Growth2.70110.2068134554600
2023-12-31Fidelity Select Biotechnology2.27770.36731134649-1900-0.1672
2023-10-31Biotech Growth Ord2.20812.3196110000019000020.8791
2023-11-30Fidelity Small Cap Value Fund1.94720.172497000000
2023-12-31Fidelity Advisor Biotechnology I1.84920.8459921195-1500-0.1626
2023-12-31Fidelity Advisor Growth Opps M1.80470.0734899000-1500-0.1666
2023-11-30Fidelity Series Small Cap Opps1.720.138885683700
2024-01-31Vanguard Total Stock Mkt Idx Inv1.66930.000883157900
2024-01-31iShares Russell 2000 ETF1.35130.0161673171-12312-1.7961
2023-11-30Fidelity Small Cap Growth K60.95510.209147579600
2023-11-30Fidelity Stock Selector Small Cap0.83610.139641650000
2024-01-31Vanguard Institutional Extnd Mkt Idx Tr0.79990.006398491-13351-3.2418
2023-11-30Fidelity Small Cap Stock0.58620.2102292025-48900-14.3433
2024-01-31iShares Russell 2000 Value ETF0.51250.0315255294-486-0.19
2023-11-30Fidelity Small Cap Index0.42720.007521280451202.4653
2024-01-31Invesco Dorsey Wright SmallCap Momt ETF0.42420.39862113046900.3276
2024-01-31iShares Biotechnology ETF0.41630.04082073913798322.421
2023-12-31Federated Hermes MDT SCC Institutional0.36150.2266180084-50749-21.9852
2023-12-31Federated Hermes MDT Small Cap Core IS0.36150.2272180084-50749-21.9852
Total 26.22026.756913061750+698308+5.3%

3.3. Insider Transactions

Insiders are holding 2.34% of the shares of Alx Oncology Holdings .

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-01-04Shelly PintoSELL271713.6
2023-07-06Shelly PintoSELL73456.52
2023-06-30Jaume PonsSELL32087.34
2023-06-30Peter S GarciaSELL8877.34
2023-06-30Shelly PintoSELL4667.34
2023-06-30Sophia RandolphSELL16057.34

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Alx Oncology Holdings  compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.882-0.593-33%-0.493-44%0.178-595%0.178-595%
Book Value Per Share--3.3874.443-24%6.573-48%4.063-17%4.063-17%
Current Ratio--5.6659.587-41%17.437-68%18.301-69%18.301-69%
Debt To Asset Ratio--0.2330.161+45%0.071+230%0.174+34%0.174+34%
Debt To Equity Ratio---0.078-100%0.065-100%0.104-100%0.104-100%
Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Eps---1.024-0.733-28%-0.608-41%-0.418-59%-0.418-59%
Free Cash Flow Per Share---0.599-0.566-5%-0.460-23%-0.326-46%-0.326-46%
Free Cash Flow To Equity Per Share---0.602-0.518-14%-0.455-24%0.193-412%0.193-412%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---38.394--------
Intrinsic Value_10Y_min---32.522--------
Intrinsic Value_1Y_max---2.100--------
Intrinsic Value_1Y_min---2.061--------
Intrinsic Value_3Y_max---7.641--------
Intrinsic Value_3Y_min---7.268--------
Intrinsic Value_5Y_max---14.788--------
Intrinsic Value_5Y_min---13.611--------
Market Cap545515860.000+56%239130240.000349977070.000-32%698085935.000-66%1076007418.737-78%1076007418.737-78%
Net Profit Margin----0%-0%-837379.7630%-837379.7630%
Operating Margin----0%-0%-795051.4400%-795051.4400%
Operating Ratio----0%-0%795051.774-100%795051.774-100%
Pb Ratio3.233+56%1.4171.561-9%2.084-32%2.479-43%2.479-43%
Pe Ratio-2.675-128%-1.172-2.587+121%-6.107+421%-14.720+1156%-14.720+1156%
Price Per Share10.950+56%4.8007.025-32%14.013-66%21.598-78%21.598-78%
Price To Free Cash Flow Ratio-4.568-128%-2.002-3.360+68%-7.934+296%-22.169+1007%-22.169+1007%
Price To Total Gains Ratio-12.415-128%-5.442-13.151+142%-30.689+464%-43.050+691%-43.050+691%
Quick Ratio--10.45717.054-39%24.718-58%21.322-51%21.322-51%
Return On Assets---0.232-0.143-38%-0.085-63%-0.106-54%-0.106-54%
Return On Equity----0.0700%-0.0730%-0.0510%-0.0510%
Total Gains Per Share---0.882-0.593-33%-0.493-44%0.178-595%0.178-595%
Usd Book Value--168752000.000221324000.000-24%327481750.000-48%202389210.526-17%202389210.526-17%
Usd Book Value Change Per Share---0.882-0.593-33%-0.493-44%0.178-595%0.178-595%
Usd Book Value Per Share--3.3874.443-24%6.573-48%4.063-17%4.063-17%
Usd Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Usd Eps---1.024-0.733-28%-0.608-41%-0.418-59%-0.418-59%
Usd Free Cash Flow---29856000.000-28217250.000-5%-22899750.000-23%-16232000.000-46%-16232000.000-46%
Usd Free Cash Flow Per Share---0.599-0.566-5%-0.460-23%-0.326-46%-0.326-46%
Usd Free Cash Flow To Equity Per Share---0.602-0.518-14%-0.455-24%0.193-412%0.193-412%
Usd Market Cap545515860.000+56%239130240.000349977070.000-32%698085935.000-66%1076007418.737-78%1076007418.737-78%
Usd Price Per Share10.950+56%4.8007.025-32%14.013-66%21.598-78%21.598-78%
Usd Profit---50990000.000-36102500.000-29%-29689500.000-42%-20167157.895-60%-20167157.895-60%
Usd Revenue----0%-0%314631.641-100%314631.641-100%
Usd Total Gains Per Share---0.882-0.593-33%-0.493-44%0.178-595%0.178-595%
 EOD+5 -3MRQTTM+4 -24YOY+4 -265Y+5 -2710Y+5 -27

4.2. Fundamental Score

Let's check the fundamental score of Alx Oncology Holdings  based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.675
Price to Book Ratio (EOD)Between0-13.233
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than110.457
Current Ratio (MRQ)Greater than15.665
Debt to Asset Ratio (MRQ)Less than10.233
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.232
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Alx Oncology Holdings  based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.063
Ma 20Greater thanMa 5014.380
Ma 50Greater thanMa 10014.430
Ma 100Greater thanMa 20012.356
OpenGreater thanClose11.100
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets220,107
Total Liabilities51,355
Total Stockholder Equity-440,800
 As reported
Total Liabilities 51,355
Total Stockholder Equity+ -440,800
Total Assets = 220,107

Assets

Total Assets220,107
Total Current Assets199,071
Long-term Assets21,036
Total Current Assets
Cash And Cash Equivalents 19,584
Short-term Investments 170,425
Net Receivables 600
Other Current Assets 9,062
Total Current Assets  (as reported)199,071
Total Current Assets  (calculated)199,671
+/- 600
Long-term Assets
Property Plant Equipment 9,808
Long Term Investments 6,435
Long-term Assets Other 4,793
Long-term Assets  (as reported)21,036
Long-term Assets  (calculated)21,036
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities35,142
Long-term Liabilities16,213
Total Stockholder Equity-440,800
Total Current Liabilities
Short-term Debt 823
Accounts payable 13,001
Other Current Liabilities 22,141
Total Current Liabilities  (as reported)35,142
Total Current Liabilities  (calculated)35,965
+/- 823
Long-term Liabilities
Long term Debt 9,575
Long-term Liabilities Other 6,638
Long-term Liabilities  (as reported)16,213
Long-term Liabilities  (calculated)16,213
+/-0
Total Stockholder Equity
Common Stock41
Retained Earnings -440,800
Accumulated Other Comprehensive Income -226
Other Stockholders Equity 185
Total Stockholder Equity (as reported)-440,800
Total Stockholder Equity (calculated)-440,800
+/-0
Other
Capital Stock41
Cash and Short Term Investments 196,444
Common Stock Shares Outstanding 41,148
Current Deferred Revenue-823
Liabilities and Stockholders Equity -389,445
Net Debt -10,009
Net Invested Capital 178,327
Net Working Capital 163,929
Property Plant and Equipment Gross 10,840
Short Long Term Debt Total 9,575



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
0
0
0
10,676
108,399
103,112
262,449
436,054
432,910
421,289
399,728
380,183
363,676
346,018
317,689
306,489
278,138
245,932
220,107
220,107245,932278,138306,489317,689346,018363,676380,183399,728421,289432,910436,054262,449103,112108,39910,676000
   > Total Current Assets 
0
0
0
9,809
107,413
100,664
262,404
434,219
432,327
412,277
388,963
367,019
321,525
316,847
290,808
270,969
232,536
219,561
199,071
199,071219,561232,536270,969290,808316,847321,525367,019388,963412,277432,327434,219262,404100,664107,4139,809000
       Cash And Cash Equivalents 
0
0
0
9,017
105,035
98,103
259,484
434,219
429,855
409,964
385,149
363,667
159,086
66,378
49,054
282,906
63,194
38,039
19,584
19,58438,03963,194282,90649,05466,378159,086363,667385,149409,964429,855434,219259,48498,103105,0359,017000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
157,510
246,988
235,855
217,385
164,750
174,797
170,425
170,425174,797164,750217,385235,855246,988157,510000000000000
       Net Receivables 
0
0
0
536
1,191
527
527
0
0
0
0
0
600
800
700
1,000
800
500
600
6005008001,000700800600000005275271,191536000
       Other Current Assets 
0
0
0
256
1,187
1,393
2,393
1,773
2,472
2,313
3,814
3,352
4,929
3,481
5,899
4,762
4,592
6,725
9,062
9,0626,7254,5924,7625,8993,4814,9293,3523,8142,3132,4721,7732,3931,3931,187256000
   > Long-term Assets 
0
0
0
867
986
2,448
45
1,835
583
9,012
10,765
13,164
42,151
29,171
26,881
35,520
45,602
26,371
21,036
21,03626,37145,60235,52026,88129,17142,15113,16410,7659,0125831,835452,448986867000
       Property Plant Equipment 
0
0
0
860
757
37
45
52
47
167
562
3,472
6,967
8,235
8,639
9,813
9,551
9,066
9,808
9,8089,0669,5519,8138,6398,2356,9673,47256216747524537757860000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
25,109
10,860
8,217
16,699
28,220
11,647
6,435
6,43511,64728,22016,6998,21710,86025,109000000000000
       Other Assets 
0
0
0
0
229
2,411
0
10
36
5,745
7,403
12,267
10,075
16,681
10,025
9,008
0
0
0
0009,00810,02516,68110,07512,2677,4035,745361002,4112290000
> Total Liabilities 
0
0
0
10,952
9,282
12,467
10,433
436,054
14,426
16,275
14,556
17,134
20,080
29,699
30,726
43,025
37,750
33,240
51,355
51,35533,24037,75043,02530,72629,69920,08017,13414,55616,27514,426436,05410,43312,4679,28210,952000
   > Total Current Liabilities 
0
0
0
4,984
3,990
7,719
7,197
6,204
14,129
13,979
12,488
15,295
15,308
23,952
25,243
28,325
21,891
17,572
35,142
35,14217,57221,89128,32525,24323,95215,30815,29512,48813,97914,1296,2047,1977,7193,9904,984000
       Short-term Debt 
0
0
0
0
857
1,714
2,571
2,571
235
539
703
742
1,025
1,075
1,117
1,041
956
800
823
8238009561,0411,1171,0751,0257427035392352,5712,5711,7148570000
       Short Long Term Debt 
0
0
0
0
857
1,714
2,571
0
0
0
0
0
0
0
0
0
0
0
0
0000000000002,5711,7148570000
       Accounts payable 
0
0
0
3,748
1,987
1,865
1,421
4
7,350
5,806
3,683
3,764
5,133
8,680
5,880
8,073
9,826
4,115
13,001
13,0014,1159,8268,0735,8808,6805,1333,7643,6835,8067,35041,4211,8651,9873,748000
       Other Current Liabilities 
0
0
0
1,236
349
301
240
6,200
103
205
102
257
9,150
14,197
18,246
19,211
11,109
13,457
22,141
22,14113,45711,10919,21118,24614,1979,1502571022051036,2002403013491,236000
   > Long-term Liabilities 
0
0
0
5,968
5,292
4,748
3,236
5
297
2,296
2,068
1,839
4,772
5,747
5,483
14,700
15,859
15,668
16,213
16,21315,66815,85914,7005,4835,7474,7721,8392,0682,29629753,2364,7485,2925,968000
       Long term Debt Total 
0
0
0
0
4,672
0
0
0
0
0
0
0
0
0
0
9,389
9,450
0
0
009,4509,38900000000004,6720000
       Other Liabilities 
0
0
0
0
620
820
47
5
0
0
0
1,839
1
5,747
0
53
0
1,309
0
01,30905305,74711,8390005478206200000
       Deferred Long Term Liability 
0
0
0
0
200
2,411
0
0
0
0
0
9,548
0
0
0
0
0
0
0
00000009,548000002,4112000000
> Total Stockholder Equity
0
0
0
-276
99,117
90,645
252,016
429,845
418,484
405,014
385,172
-201,985
343,596
316,319
286,963
-325,467
240,388
212,692
-440,800
-440,800212,692240,388-325,467286,963316,319343,596-201,985385,172405,014418,484429,845252,01690,64599,117-276000
   Common Stock
0
0
0
3
3
3
37
40
40
40
40
41
41
41
41
41
41
41
41
41414141414141414040404037333000
   Retained Earnings Total Equity00-355,651-325,467-294,758-259,438-226,518-201,985-173,547-148,981-132,707-118,5220000000
   Accumulated Other Comprehensive Income -226-312-88-845-1,504-1,256-606000-300-97-92-1,563-1,449000
   Capital Surplus 
0
0
0
0
2,289
0
0
548,327
551,151
553,955
558,679
564,993
570,679
576,972
583,184
589,735
596,086
0
0
00596,086589,735583,184576,972570,679564,993558,679553,955551,151548,327002,2890000
   Treasury Stock0000000000000000000
   Other Stockholders Equity 
0
0
0
3,589
3,870
5,258
89,375
548,327
551,181
553,955
558,679
-41
570,679
576,972
583,184
804
596,086
602,773
185
185602,773596,086804583,184576,972570,679-41558,679553,955551,181548,32789,3755,2583,8703,589000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-154,474
Operating Income-154,474-154,474
 
Operating Expense (+$)
Research Development125,208
Selling General Administrative29,266
Selling And Marketing Expenses-
Operating Expense154,474154,474
 
Net Interest Income (+$)
Interest Income9,461
Interest Expense--
Other Finance Cost-1,143
Net Interest Income8,318
 
Pretax Income (+$)
Operating Income-154,474
Net Interest Income8,318
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-145,978-154,652
EBIT - interestExpense = 0
-146,042
-146,042
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--145,978
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-145,978
Tax Provision--
Net Income From Continuing Ops-146,042-145,978
Net Income-146,042
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net178-8,318
 

Technical Analysis of Alx Oncology Holdings 
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Alx Oncology Holdings . The general trend of Alx Oncology Holdings  is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Alx Oncology Holdings 's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Alx Oncology Holdings .

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 12.45 < 12.47 < 13.36.

The bearish price targets are: 10.49 > 10.16 > 10.16.

Tweet this
Alx Oncology Holdings  Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Alx Oncology Holdings . The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Alx Oncology Holdings  Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Alx Oncology Holdings . The current macd is -0.90781794.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Alx Oncology Holdings  price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Alx Oncology Holdings . This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Alx Oncology Holdings  price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Alx Oncology Holdings  Daily Moving Average Convergence/Divergence (MACD) ChartAlx Oncology Holdings  Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Alx Oncology Holdings . The current adx is 18.97.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Alx Oncology Holdings  shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Alx Oncology Holdings  Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Alx Oncology Holdings . The current sar is 14.62.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Alx Oncology Holdings  Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Alx Oncology Holdings . The current rsi is 32.06. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Alx Oncology Holdings  Daily Relative Strength Index (RSI) ChartAlx Oncology Holdings  Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Alx Oncology Holdings . The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Alx Oncology Holdings  price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Alx Oncology Holdings  Daily Stochastic Oscillator ChartAlx Oncology Holdings  Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Alx Oncology Holdings . The current cci is -156.15813409.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Alx Oncology Holdings  Daily Commodity Channel Index (CCI) ChartAlx Oncology Holdings  Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Alx Oncology Holdings . The current cmo is -48.71835301.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Alx Oncology Holdings  Daily Chande Momentum Oscillator (CMO) ChartAlx Oncology Holdings  Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Alx Oncology Holdings . The current willr is -96.96969697.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Alx Oncology Holdings  Daily Williams %R ChartAlx Oncology Holdings  Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Alx Oncology Holdings .

Alx Oncology Holdings  Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Alx Oncology Holdings . The current atr is 1.16015802.

Alx Oncology Holdings  Daily Average True Range (ATR) ChartAlx Oncology Holdings  Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Alx Oncology Holdings . The current obv is 61,110,129.

Alx Oncology Holdings  Daily On-Balance Volume (OBV) ChartAlx Oncology Holdings  Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Alx Oncology Holdings . The current mfi is 22.74.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Alx Oncology Holdings  Daily Money Flow Index (MFI) ChartAlx Oncology Holdings  Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Alx Oncology Holdings .

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-10-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-10-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-31CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-11-02MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-11-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Alx Oncology Holdings  Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Alx Oncology Holdings  based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.063
Ma 20Greater thanMa 5014.380
Ma 50Greater thanMa 10014.430
Ma 100Greater thanMa 20012.356
OpenGreater thanClose11.100
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Alx Oncology Holdings  with someone you think should read this too:
  • Are you bullish or bearish on Alx Oncology Holdings ? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Alx Oncology Holdings ? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Alx Oncology Holdings 

I send you an email if I find something interesting about Alx Oncology Holdings .


Comments

How you think about this?

Leave a comment

Stay informed about Alx Oncology Holdings .

Receive notifications about Alx Oncology Holdings  in your mailbox!